This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Streptorix, PHiD-CV, GSK1024850A
Streptorix is a pneumococcal conjugate vaccine designed to provide protection against the 10 most important pneumococcal serotypes worldwide. Streptorix combines the seven strains of Streptococcus pneumoniae that are currently included in Wyeth's Prevnar (4, 6B, 9V, 14, 18C, 19F, and 23F) with four additional strains (1, 3, 5, and 7F). The 10 types covered by Streptorix represent about 80% of circulating invasive S. pneumoniae serotypes worldwide. Importantly, and in contrast to its competitor Prevnar, Synflorix does not include coverage for serotype 19a, the most common serotype in the US.
In contrast to Prevnar, in which the seven strains are conjugated to a nontoxic mutant of diphtheria toxin (CRM 197), the 11 pneumococcal serotypes of Streptorix are conjugated to a carrier protein derived from H. influenzae.
Additional information available to subscribers only: